Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response
Ibrahim Turkoz, Ella Daly, Jaskaran Singh, Xiwu Lin, Yevgen Tymofyeyev, David Williamson, Giacomo Salvadore, Abigail I. Nash, Matthew Macaluso, Samuel T. Wilkinson, J. Craig Nelson
The Journal of Clinical Psychiatry July 16, 2021 DOI: 10.4088/jcp.20m13800 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pooled post hoc analysis of two phase 3, double-blind, active-controlled studies Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Duration | 4-week induction course |
| Topics | Anxiety Depression Esketamine |
| Keywords | Antidepressant Depression economics Nasal spray Anesthesia Nasal administration Pharmacology |
| Citations | 21 |
| Registration | NCT02417064 NCT02418585 |
| Key points | Patients with treatment-resistant depression who did not respond within the first week of treatment may still benefit from a full 4-week induction course of esketamine nasal spray. |
Abstract
) and treatment-resistant depression (TRD) who did not meet response criteria within the first week of treatment. The current study is a pooled post hoc analysis of two phase 3, double-blind, active-controlled studies, conducted between August 2015 and February 2018, comparing ESK + AD with an oral antidepressant plus placebo (AD + PBO). Early treatment response was defined as a ≥ 50% decrease in Montgomery-Åsberg Depression Rating Scale total score at day 2 or days 2 and 8. Response rates at day 28 were determined among those not meeting early response criteria. = .01). In nonresponders at day 2 and at days 2 and 8, the odds ratio for a response at day 28 was 1.61 (95% CI, 1.09-2.40) with ESK + AD versus 1.56 (95% CI, 1.04-2.35) with AD + PBO. Patients with TRD without a demonstrated response within the first week of treatment may still derive benefit from a full 4-week induction course of esketamine nasal spray. ClinicalTrials.gov identifiers NCT02417064 and NCT02418585.
Comparable studies
Other randomized controlled trials on esketamine for anxiety, most cited first.
Citations in the library
Cited by 10
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry March 1, 2025
- Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. Psychopharmacology April 1, 2023
- Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray Psychiatry Research March 15, 2023
- A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study. Advances in Therapy May 1, 2025
- Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. CNS Spectrums June 1, 2024
and 5 more in the library